Press Releases

Oxford Biomedica notes the announcement that Kymriah® has received FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma

Oxford, UK – 22nd April, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, notes the announcement from Novartis that the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Kymriah® (tisagenlecleucel), for an investigational new… Read More

Notice of Results Update

Full Year Results to be Published on 6th May 2020 Oxford, UK – 16th April, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announces today that, following guidance from the Financial Reporting Council (FRC) and Financial Conduct Authority (FCA) in… Read More

Oxford Biomedica joins Consortium to rapidly develop a COVID-19 vaccine candidate

Consortium led by Jenner Institute, University of Oxford Fast-tracked clinical trial of ChAdOx1 nCOV-19 vaccine candidate starts this month Oxford, UK – 8th April, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today it has joined a… Read More

Oxford Biomedica Signs License & Clinical Supply Agreement with Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, for LentiVector® Platform for CAR-T and TCR-T Therapeutics

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. Oxford,… Read More

Building the Group for future growth

Business Update Oxford, UK – 18 March 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announces today an unaudited trading and business update to 31 December 2019 and post period end review. The Group expects to announce its preliminary results on… Read More

Oxford Biomedica Extends Commercial Supply Agreement by Five Years for Manufacture of Lentiviral Vectors

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. Oxford,… Read More

Interim results for the six months ended 30 June 2019

Oxford, UK – 4 September 2019: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announces interim results for the six months ended 30 June 2019. FINANCIAL HIGHLIGHTS Revenues were £32.1 million, a decrease of 9% (H1 2018: £35.3 million) reflecting… Read More

Oxford Biomedica and Santen enter R&D collaboration and Option & Licence Agreement for development of gene therapy vectors for inherited retinal disease

June 26, 2019, Oxford, UK and Osaka Japan–Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, and Santen Pharmaceutical Co., Ltd. (Santen), the market leader for prescription ophthalmic pharmaceuticals in Japan with a global presence in over 60 countries, today announced that they have entered into an R&D… Read More

Exercise of Subscription Option by Novo Holdings

Oxford, UK – 29 May 2019: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today announces that, further to the announcement of 28 May in relation to Novo Holdings’ agreement to subscribe for 6,568,024 new ordinary shares in Oxford Biomedica (the “Subscription Shares”) at a price… Read More

Oxford Biomedica announces strategic investment by Novo Holdings A/S

Oxford, UK – 28 May 2019: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today announces that Novo Holdings A/S (“Novo Holdings”), has agreed to invest up to £53.5 million in the Group in return for new ordinary shares representing up to… Read More

Oxford Biomedica to present at the Annual Meeting of the American Society of Gene & Cell Therapy

Oxford, UK – 30 April 2019: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today announced that data from five studies will be highlighted in two oral presentations and three poster sessions at the American Society of Gene & Cell Therapy 22nd Annual Meeting, taking place between… Read More

Oxford Biomedica notes that Axovant has announced the dosing of the first patient in the second cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD

– Under terms of the agreement with Axovant signed in June 2018, this has triggered a $15 million milestone to Oxford Biomedica Oxford, UK – 30 April 2019: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, notes that Axovant Gene Therapies Ltd. (NASDAQ: AXGT) has announced the… Read More

Press Releases

News from the year: /2015